Plain-English translation of NCT07266831 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing two new HIV medications — islatravir and ulonivirine — that you would take just once a week as a single pill. Researchers want to see if this once-weekly combination works as well as the standard HIV treatment, which requires taking three medicines once or twice daily. The study will follow you for nearly two years to compare how well the medication controls your HIV and how you tolerate it.
Current HIV treatments work well but require taking multiple pills daily, which can be inconvenient and sometimes cause side effects. This trial is exploring whether a simpler once-weekly option could make HIV treatment easier to stick with while being just as effective.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to take either the new once-weekly medication or the standard daily treatment for 96 weeks (nearly two years). You'll visit the research site regularly for check-ups, blood tests to measure your viral load and CD4 count, and to discuss how you're tolerating the medication. The study is designed so that in later phases, some participants won't know which treatment they're receiving, which helps researchers get accurate results.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States